Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prospective, Multi-Center, Observational, Program to Assess Retention Rate, Persistence and Adherence in Population of Spondylarthritis (Ankylosing Spondylitis and Psoriatic Arthritis) Patients Treated With Adalimumab in Routine Clinical Settings in Russian Federation

NCT02988674 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT02988674
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02988674 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prospective, Multi-Center, Observational, Program to Assess Retention Rate, Persistence and Adherence in Population of Spondylarthritis (Ankylosing Spondylitis and Psoriatic Arthritis) Patients Treated With Adalimumab in Routine Clinical Settings in Russian Federation
Lead sponsor
AbbVie
Phase
Observational
Overall status
Completed
Start date
December 22, 2016
Completion date
October 16, 2019
Enrollment
139 (actual)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

ankylosing spondylitis (as), psoriatic arthritis, spondylarthritis